Drug intelligence / Profile preview

Program 2201

Development stage: Preclinical
Lead developer: Apeiron Therapeutics
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

Program 2201 is a preclinical drug candidate developed by Apeiron Therapeutics, described as a PPI (protein-protein interaction) modulator. It is part of the company's pipeline and has been identified as a "Hit ID" stage program, indicating it is in early discovery or lead identification phases. There are no details available regarding its specific molecular target, mechanism of action, or therapeutic indication at this time. The program has not reached clinical trials and remains in the research and development phase[7].

Beyond the preview

Go deeper on Program 2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Program 2201.

Explore the full profile